Exercise of License Option. The option of Article 8.1 must be exercised by written notice mailed within three (3) months after the patent or other IP application is filed to: CDC Technology Transfer Coordinator Centers for Disease Control ▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇, N.E. Building 1, B72, Mailstop A20 ▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇ ▇▇▇▇▇ [***] Confidential Treatment Requested Exercise of this option by the Collaborator initiates a negotiation period that expires nine (9) months after the patent or other IP application filing date. If the last proposal by the Collaborator has not been responded to in writing by CDC within this nine (9) month period, the negotiation period shall be extended to expire one (1) month after CDC so responds, during which month the Collaborator may accept in writing the final license proposal of CDC. After that time, CDC will be free to license such IP rights to others.
Appears in 2 contracts
Sources: Cooperative Research and Development Agreement (Progenics Pharmaceuticals Inc), Cooperative Research and Development Agreement (Progenics Pharmaceuticals Inc)